Atsuko Ogiso

ORCID

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 6

Top Venues

Breast cancer (Tokyo, Japan)

This page only lists publications with an associated author ORCID identifier.

Publications

Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) 30 (2) (2023)
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) 30 (2) (2023)
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) (2023)
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) 30 (2) (2023)
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) 30 (2) (2023)
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) 30 (2) (2023)

Atsuko Ogiso.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Atsuko Ogiso